144 related articles for article (PubMed ID: 38929525)
1. Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929525
[No Abstract] [Full Text] [Related]
2. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
4. Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process.
Hachuła M; Kosowski M; Ryl S; Basiak M; Okopień B
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339133
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
6. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
7. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Tanaka K; Okada Y; Tokutsu A; Tanaka Y
Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
11. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
14. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
Ghosh A; Nair R
Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
[TBL] [Abstract][Full Text] [Related]
15. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
Da Porto A; Casarsa V; Colussi G; Catena C; Cavarape A; Sechi L
Diabetes Metab Syndr; 2020; 14(4):289-292. PubMed ID: 32289741
[TBL] [Abstract][Full Text] [Related]
16. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
18. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
[TBL] [Abstract][Full Text] [Related]
19. Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Sanada J; Kimura T; Shimoda M; Tomita A; Fushimi Y; Kinoshita T; Obata A; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():714447. PubMed ID: 34484124
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
